NCT06651151View on ClinicalTrials.gov

NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2031

Conditions
Melanoma Stage IIIB-IV
Interventions
DRUG

LTX-315 + pembrolizumab

LTX-315 as intratumoral injection once weekly for a maximum of 5 dosing days, in combination with pembrolizumab as intravenous infusion, 200 mg every 3 weeks for a maximum of 18 doses

Trial Locations (1)

0491

RECRUITING

Oslo University Hospital, Oslo

Sponsors

Collaborators (1)

Lytix Biopharma AS
All Listed Sponsors
collaborator

Lytix Biopharma AS

INDUSTRY

lead

Oslo University Hospital

OTHER

NCT06651151 - NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma | Biotech Hunter | Biotech Hunter